Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PDD00017273 is a radiosensitizing PARG) inhibitor with antitumor or activity for the study of epithelial ovaries.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 75.00 | |
10 mg | In stock | $ 139.00 | |
25 mg | In stock | $ 298.00 | |
50 mg | In stock | $ 447.00 | |
100 mg | In stock | $ 645.00 | |
500 mg | In stock | $ 1,330.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 88.00 |
Description | PDD00017273 is a radiosensitizing PARG) inhibitor with antitumor or activity for the study of epithelial ovaries. |
Targets&IC50 | PARG:1.45 nM (Kd), PARG:26 nM |
In vitro | PDD 00017273 is an effective inhibitor of PARG with an IC50 of 26 nM and a KD of 1.45 nM. At 10 μM, PDD 00017273 does not inhibit five common cytochrome P450 enzymes. At 30 μM, it moderately increases phosphorylated H2AX (γH2AX) intensity. Additionally, PDD 00017273 reduces NAD/H through PARG inhibition after DNA damage. The compound inhibits ZR-75-1 cells carrying wild-type BRCA1 and BRCA2 and exhibits weaker activity against MDA-MB-436 cells carrying the 5396 + 1G>A mutation in BRCA1[2].At 0.3 μM, PDD 00017273 inhibits the degradation of PAR polymers in MCF7 cells. It also reduces the viability of BRCA1, BRCA2, PALB2, FAM175A, and BARD1-depleted cells. PDD 00017273 halts replication forks and induces DNA damage requiring homologous recombination (HR) for repair[1]. |
Molecular Weight | 514.62 |
Formula | C23H26N6O4S2 |
CAS No. | 1945950-21-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20 mg/mL (38.86 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PDD00017273 1945950-21-9 Others PDD 00017273 PDD-00017273 inhibitor inhibit